dihydropyrimidin
import
heterocycl
ring
system
play
import
role
synthesi
dna
rna
synthet
synthes
use
multicompon
reaction
like
biginelli
reaction
hantzschdihydropyridin
past
decad
biginelli
type
dihydropyrimidon
receiv
consider
amount
attent
due
interest
pharmacolog
properti
associ
heterocycl
scaffold
review
highlight
recent
develop
area
focu
dhpm
recent
develop
antiinflammatori
antihiv
antitubercular
antifung
anticanc
antibacteri
antifilari
antihyperglycem
antihypertens
analges
anticonvuls
antioxid
antisar
anticanc
activ
bind
affin
dhpm
melaninconcentr
hormon
heterocycl
chemistri
import
branch
organ
chemistri
account
nearli
onethird
modern
public
heterocycl
compound
vital
role
biolog
system
integr
part
mani
pharmacolog
activ
molecul
natur
product
nucleic
acid
base
pair
dna
rna
guanin
cytosin
adenin
thymin
also
made
heterocycl
compound
like
purin
pyrimidin
etc
heterocycl
compound
also
present
larg
varieti
drug
candid
like
antitumor
antibiot
antiinflammatori
antidepress
antimalari
antihiv
antimicrobi
antibacteri
antifung
antivir
antidiabet
herbicid
fungicid
insecticid
agent
natur
occur
molecul
discov
good
biolog
activ
mani
diseas
eg
quinin
use
antimalari
drug
vinblastin
vincristin
also
use
anticanc
agent
review
focu
dhpm
ring
basic
select
review
dihydropyrimidinon
literatur
last
two
decad
incorpor
review
pyrimidin
import
heterocycl
moieti
pyrimidin
deriv
variou
therapeut
applic
medicin
chemistri
one
anticip
reason
activ
presenc
pyrimidin
base
thymin
cytosin
uracil
essenti
build
block
nucleic
acid
dna
rna
number
chemic
compound
consist
pyrimidin
core
nucleu
synthes
evalu
antihypertens
anticanc
antimicrobi
antihyperglycem
antiarrhythm
antiinflammatori
analges
antibacteri
antihiv
antitubercular
activ
due
wide
rang
therapeut
properti
scientist
attract
toward
develop
new
dihydropyrimidin
molecul
recent
dragovich
et
al
synthes
substitut
inhibitor
human
lactat
dehydrogenas
dhpm
synthes
help
multicompon
reaction
mcr
mcr
special
type
theoret
use
organ
reaction
three
start
materi
react
give
desir
product
combin
synthesi
pathway
gener
show
advantag
continu
atyp
approach
respect
time
speed
yield
reproduc
among
organ
reaction
mcr
two
start
materi
allow
form
complex
product
therefor
constitut
superior
tool
divers
orient
complexitygener
synthesi
drug
discoveri
commonli
use
multi
compon
reaction
heterocycl
synthesi
biginelli
reaction
hantzsch
dihydropyridin
synthesi
etc
pharmacolog
activ
dihydropyrimidinon
shown
fig
dihydroprymidinon
nucleu
also
found
marin
natur
alkaloid
batzelladin
b
known
inhibit
bind
hiv
cell
variou
synthet
analog
monastrol
sq
develop
fig
monastrol
import
anticanc
compound
abil
cross
cell
membran
caus
mitosi
revers
specif
inhibit
myosin
kinas
variou
analog
monstraol
oxomonastrol
thio
deriv
manostrol
develop
test
colon
cancer
cell
line
analog
found
time
potent
monastrol
variou
drug
interact
side
effect
report
drug
contain
dihyropyrimidinon
nucleu
monastrol
well
known
mitot
kinesin
inhibitor
found
neurotox
one
major
side
effect
interact
aminophyllin
topiram
studi
care
reveal
aminophyllin
contain
dihyroprymidinon
nucleu
markedli
attenu
anticonvuls
potenti
topiram
mous
maximalelectroshockinduc
seizur
model
seizur
prolong
action
aminophyllin
also
observ
mainli
attribut
block
adenosin
receptor
howev
seizur
prolong
action
aminophyllin
antagon
ro
partial
benzodiazepin
agonist
interact
misonidazol
reveal
clearanc
former
significantli
reduc
misonidazol
radiosensitis
hypox
cell
shown
enhanc
antitumor
activ
sever
chemotherapi
drug
research
develop
past
year
effect
accomplish
purpos
introduct
variou
synthet
strategi
numer
synthet
strategi
outlin
synthesi
dhpm
illustr
scheme
pietro
bignelli
report
synthesi
dihydropyrimidin
monastrol
condens
ethyl
acetoacet
thiourea
slightli
acid
condit
use
concentr
hydrochlor
acid
catalyst
appropri
solvent
ethanol
matthew
et
al
treat
bketo
ester
aldehyd
urea
synthesi
dhpm
holla
et
al
publish
one
pot
synthesi
thiazolodihydropyrimidinon
condens
thiourea
presenc
sodium
hydroxid
ethanol
potassium
hydroxid
claisenschmidt
reaction
condit
yadlap
et
al
synthes
dhpm
help
benzaldehyd
excess
thiourea
ethanol
mild
acid
condit
provid
expect
dhpm
good
excel
yield
shaabni
et
al
describ
synthesi
new
class
one
deriv
onepot
process
fourcompon
condens
reaction
aliphat
aromat
amin
diketen
aromat
aldehyd
ureathiourea
presenc
ptoluenesulfon
acid
ptsohh
catalyst
dichloromethan
ambient
temperatur
sinc
number
possibl
combin
fourcompon
reaction
greater
threecompon
reaction
divers
biginelli
reaction
explor
fourcompon
reaction
strategi
variou
effici
method
synthesi
dihydropyrimidin
develop
past
decad
well
describ
scheme
still
variou
recent
altern
approach
report
synthesi
attract
molecul
describ
scheme
multicompon
reaction
success
gener
complex
molecul
report
use
bcyclodextrinpropyl
sulfon
acid
mol
catalyst
synthesi
onepotmulticompon
reaction
benzaldehyd
urea
thiourea
ethyl
acetoacet
solventfre
condit
c
cyclodextrin
macrocycl
oligosaccharid
possess
hydrophob
caviti
bind
substrat
via
noncoval
interact
properti
cyclodextrin
util
variou
applic
benazzouz
et
al
describ
simpl
effici
synthet
startegi
new
seri
onesthion
reaction
initi
use
acetoacetyl
coumarin
deriv
key
synthon
parasubstitut
benzaldehyd
ureathiourea
presenc
sulfur
acid
act
catalyst
reflux
acetonitril
saher
et
al
synthes
use
keggin
dawson
type
polyoxometal
acid
catalyst
keggin
type
polyoxometal
acid
oxid
properti
mainli
depend
upon
natur
compon
composit
easili
modifi
accord
reaction
need
bignelli
reaction
carri
use
two
solvent
etoh
polar
protic
mecn
polar
aprot
reflux
condit
condens
ethylmethyl
acetoacet
benzaldehyd
urea
presenc
h
simo
catalyst
use
ethanol
mecn
solvent
h
afford
one
moder
good
yield
treptow
et
al
report
fatti
acid
synthesi
util
bignelli
multicompon
reaction
reaction
carri
react
aromat
aldehyd
urea
thiourea
bketoest
presenc
catalyt
amount
incl
use
acetonitril
solvent
therebi
afford
dhpmfatti
acid
synthesi
good
excel
yield
qiu
et
al
describ
cerium
iii
trislaurylsulfon
ce
ls
effici
stabl
catalyst
combin
lewi
acid
surfact
catalyst
ultilis
catalys
onepot
bignelli
well
solvent
free
esterif
reaction
obtain
yield
employ
reaction
benzaldehyd
ethylacetoacet
urea
presenc
catalyt
amount
ce
c
h
one
drop
conc
hcl
ethanol
c
h
describ
scheme
catalyst
sio
cucl
silica
support
copper
ii
chlorid
onepot
synthesi
dhpm
microwav
thermal
condit
reaction
carri
similar
substrat
benzaldehyd
urea
ethylacetoacet
compar
studi
undertaken
use
solventfre
condit
c
use
diphen
acid
thermal
condit
condit
microwav
exposur
c
acetonitril
without
use
diphen
acid
condit
b
describ
scheme
diphen
acid
use
provid
polar
condit
reaction
make
carbonyl
group
aldehyd
polar
nucleophileelectrophil
attack
found
reaction
carri
microwav
radiat
fast
clean
produc
excel
yield
structureact
relationship
studi
also
conduct
condit
found
case
aromat
aldehyd
substitut
electrondon
group
afford
yield
aromat
aldehyd
substitut
electronwithdraw
group
afford
yield
heteroaromat
aldehyd
end
yield
case
aliphat
aldehyd
like
formaldehyd
produc
yield
wherea
acetaldehyd
butan
afford
product
trace
amount
mani
synthet
approach
conduct
solventfre
condit
synthesi
one
use
bignelli
reaction
condit
describ
good
yield
obtain
reaction
carri
use
aliphat
aldehyd
bismuth
nitrat
catalyst
howev
bignelli
reaction
carri
use
bismuth
nitrat
acetonitril
effect
microwav
radiat
absenc
solvent
product
obtain
quanit
yield
mansoor
et
al
describ
synthesi
dhpm
use
triphenylphoshphin
mol
catalyst
solvent
free
condit
c
h
use
similar
three
compon
substrat
aromat
aldehyd
ureathiourea
bketoest
triphenyphosphin
act
lewi
base
interact
electrophil
carbon
aldehyd
enol
bketoest
form
coordin
aldehyd
pph
help
deproton
bketoest
attri
et
al
util
triethylammoniumaceta
teaa
catalyst
reaction
medium
synthesi
deriv
solvent
free
condit
use
aldehyd
ureathiourea
bketoest
subtrat
reaction
yield
obtain
upto
teaa
rel
inexpens
thermost
nontox
recycl
vast
applic
catalyst
reaction
medium
apart
classic
method
bignelli
reaction
focu
also
shift
catalyt
asymmetr
bignelli
reaction
order
obtain
enantiomer
pure
dhpm
subdivid
two
categori
metalcatalyz
enantioselect
bignelli
reaction
organocatalyt
enantioselect
bignelli
reaction
case
metalcatalyz
reaction
juaristi
report
enantioselect
synthesi
dhpm
utils
cecl
incl
catalys
bignelli
reaction
presenc
chiral
ligand
differ
chiral
ligand
employ
cecl
incl
achiev
best
enantioselect
synthesi
found
ligand
r
r
show
best
result
induc
enantioselect
wherea
ligand
benzylamin
reveal
stereoselect
synthesi
directli
incorpor
aldehyd
compon
reaction
occur
intermedi
ethylacetoacet
c
c
highest
enantioselect
obtain
upto
ee
describ
scheme
chen
et
al
co
worker
abl
synthes
seri
chiralphosphor
acid
act
catalyst
enantioselect
synthesi
bignelli
reaction
chiral
phosphor
acid
term
h
binobas
phosphor
acid
found
effect
provid
product
yield
upto
enantioselect
observ
use
threecompon
substrat
aldehyd
ureathiourea
bketoest
thorat
cowork
report
metal
free
oaryl
one
sacffold
bignelli
type
produc
pyrimidin
deriv
appropri
yield
use
diaryliodonium
salt
catalyst
metal
free
condit
oaryl
one
carri
presenc
diphenyliodonium
triflat
k
co
base
presenc
toluen
afford
yield
describ
scheme
karami
et
al
describ
onepot
reaction
aryl
gloxal
urea
ethylacetoacet
use
molybd
sulfur
acid
catalyst
furnish
novel
aryloyl
yield
solvent
free
condit
reaction
accord
green
chemistri
principl
undergo
knorrcondens
hydrazin
produc
pyrimido
pyrazin
abr
anyibalogh
et
al
publish
versatil
build
block
found
use
start
materi
bignelli
type
reaction
compound
success
react
urea
four
differ
bdioxocompound
ethyl
acetoacet
ethyl
isobutyrylacet
ethyl
benzoylacet
reaction
catalyz
nicl
ethanol
contain
catalyt
amount
conc
hcl
solvent
afford
product
deriv
yield
describ
scheme
biolog
investig
dihydropyrimidin
involv
variou
mechan
like
enzymat
action
receptor
mediat
mechan
activ
ion
channel
etc
biolog
investig
reveal
substitut
variou
group
ring
impart
differ
activ
outlin
differ
activ
dhpm
shown
fig
kumar
et
al
synthes
evalu
novel
aryl
acet
acid
deriv
potenti
antiinflammatori
agent
antiinflammatori
activ
compound
record
basi
refer
standard
drug
diclofenac
sodium
compound
show
tendenc
prevent
edema
show
antiinflammatori
activ
compound
test
antiinflammatori
activ
accord
method
winter
et
al
albino
rat
employ
carageenan
induc
rat
paw
edema
test
percentag
reduct
inflamm
h
administr
carageenan
record
test
compound
scheme
enantioselect
synthesi
use
chiral
ligand
compar
anim
administr
carangeenan
use
refer
standard
diclofenac
sodium
synthes
three
seri
molecul
differ
function
group
mention
r
r
fig
observ
differ
molecul
shown
antiinflammatori
activ
compound
found
potent
among
molecul
presenc
group
play
import
role
activ
compound
observ
phenyl
increas
activ
compound
hand
phenyl
group
reduc
activ
compound
phenyl
group
replac
pchlorophenyl
phenyl
activ
compound
found
increas
methoxi
group
replac
group
activ
decreas
structur
inhibitori
percentag
valu
ip
compound
given
fig
evalu
enzymat
activ
hiv
integras
compound
inhibit
strand
transfer
submicromolar
activ
observ
substitut
play
import
role
potenc
compound
r
substitut
methyl
ethyl
group
enhanc
activ
observ
hand
r
substitut
phenyl
isopropyl
group
decrement
effect
activ
observ
prove
steric
hindranc
toler
structur
potent
compound
given
fig
ic
valu
shown
tabl
respect
differ
substitut
r
r
r
differenti
help
differ
color
trivedi
et
al
synthes
novel
dihydropyrimidin
potenti
new
class
antitubercular
agent
synthes
thirti
new
molecul
multicompon
biginelli
reaction
initi
nine
compound
screen
help
mycobacterium
tuberculosi
strain
inhibit
mtb
upto
secondari
level
two
compound
inhibit
mtb
mic
mgml
three
compound
mic
mgml
among
compound
compound
found
potent
compound
mic
mgml
si
seri
compound
found
much
better
exist
drug
inh
mic
mgml
vitro
studi
compound
gave
direct
develop
excel
lead
novel
antitubercular
activ
molecul
fourth
posit
phenyl
ring
pyrazolyl
play
import
role
activ
newli
develop
molecul
posit
phenyl
ring
pyrazolyl
substitut
differ
electroneg
element
instead
methyl
group
compound
found
activ
structur
potent
compound
tuberculosi
shown
fig
summar
data
given
tabl
respect
ali
kamal
develop
novel
fuse
chromeno
pyrimidin
pyrano
pyrimidin
deriv
screen
newli
prepar
compound
done
separ
vitro
antifung
activ
compound
test
two
fungal
speci
name
fungu
aspergillu
flavu
one
yeast
fungu
candida
albican
sabouraund
dextros
agar
plate
antifung
activ
measur
agar
well
diffus
method
nine
compound
test
antifung
activ
test
perform
three
time
fungu
test
compound
compar
standard
amphotericin
b
evalu
potenc
zone
inhibit
determin
synthes
compound
result
summar
tabl
result
obtain
conclud
compound
potent
standard
drug
amphotericin
b
aspergillu
flavu
fungu
hand
found
inact
candida
albican
fungu
structur
potent
compound
shown
fig
summar
data
given
tabl
respect
rajanarendar
et
al
synthes
antibacteri
novel
piperazin
morpholin
link
substitut
pyrimidin
deriv
antimicrobi
agent
newli
synthes
compound
estim
vitro
antibacteri
differ
type
gramposit
gramneg
bacteri
use
broth
dilut
method
result
shown
tabl
ciprofloxacin
use
standard
drug
comparison
bacteri
strain
use
present
studi
bacillu
subtili
mtcc
bacillu
sphaericu
mtcc
staphylococcu
aureu
mtcc
pseudomona
aeruginosa
mtcc
klebsiella
aerogen
mtcc
chromobacterium
violaceum
mtcc
result
show
compound
averag
good
antibacteri
activ
activ
standard
drug
ciprofloxacin
activ
shown
term
minimum
inhibitori
concentr
mic
sar
studi
disclos
benzen
ring
substitut
electron
withdraw
group
like
chloro
bromo
enhanc
activ
compound
compound
found
potent
compound
exhibit
antibacteri
activ
compar
standard
drug
ciprofloxacin
structur
potent
compound
shown
fig
summar
data
given
tabl
respect
see
fig
attri
et
al
also
report
antibacteri
activ
synthes
compound
shown
fig
compound
evalu
use
disk
diffus
assay
zone
inhibit
measur
assay
method
involv
pour
nutrient
agar
ml
petri
dish
asept
condit
laminar
flow
hood
plate
kept
solidif
solidif
ml
fresh
cultur
spread
onto
surfac
solidifi
medium
plate
left
dri
laminar
fashion
dri
five
plain
steril
disk
place
plate
ml
test
solut
differ
concentr
ppm
load
onto
individu
disk
commerci
avail
ampicillin
use
control
plate
plate
kept
incub
c
h
plate
taken
incub
zone
inhibit
record
test
compound
control
experi
conduct
triplic
treatment
bacterium
mic
minimum
inhibitori
concentr
defin
lowest
possibl
concentr
test
compound
abl
inhibit
organ
measur
use
microdilut
assay
determin
basi
serial
dilut
method
vari
concentr
test
compound
rang
mgml
requisit
concentr
test
compound
ad
steril
erlenmey
flask
contain
ml
nutrient
broth
sonic
min
flask
inocul
ml
freshli
prepar
bacteri
suspens
e
coli
aureu
p
aeruginosa
k
pneumonia
order
maintain
initi
bacteri
concentr
cfuml
flask
incub
orbit
shaker
rpm
c
bacteri
growth
monitor
use
spectrophotomet
use
increas
absorb
nm
experi
includ
posit
control
flask
contain
test
compound
nutrient
media
absenc
inoculum
well
neg
control
flask
inoculum
test
compound
test
compound
experi
perform
triplic
compound
possess
moder
good
inhibitori
activ
show
good
antibacteri
activ
bacteria
possibl
attribut
due
presenc
halogen
atom
compound
found
effect
bacteria
lower
mic
comparison
compound
due
presenc
two
halogen
atom
compound
tend
enhanc
antibacteri
activ
singh
et
al
synthes
antifilari
agent
synthes
compound
evalu
vitro
macrofilaricid
activ
brugia
malayi
accord
method
murthi
chatterje
microand
macrofilaricid
activ
evalu
method
describ
lammler
wolf
chatterje
gaur
conclud
compound
show
complet
loss
motil
adult
worm
b
malayi
mm
concentr
shown
inhibit
mtt
reduct
assay
compound
show
inhibit
mtt
reduct
assay
compound
affect
motil
irrevers
loss
mtt
reduct
inhibit
mtt
reduct
assay
sar
studi
show
substitut
less
bulki
electronwithdraw
group
fourth
posit
phenyl
ring
compound
best
compound
seri
three
compound
found
potent
vitro
antiflari
activ
structur
synthes
compound
shown
fig
data
potent
compound
summar
tabl
bhosl
et
al
synthes
thiazolyl
methoxyphenyl
pyrimidin
evalu
antihyperglycaem
activ
antihyperglycaem
activ
evalu
male
albino
rat
spragu
dawley
strain
present
data
show
normoglycem
rat
compound
exhibit
glycaem
control
decreas
peak
blood
glucos
area
oral
sucros
toler
ostt
curv
h
sucros
load
indic
enhanc
glucos
util
may
provok
either
insulin
product
pancreat
b
cell
inhibit
intestin
aglucosidas
enzym
respons
breakdown
polysaccharid
monomer
form
thu
inhibit
postprandi
hyperglycaemia
amongst
screen
compound
reduc
blood
glucos
level
normal
rat
activ
test
compound
compar
standard
drug
metformin
compound
number
notabl
reluct
postprandi
rise
blood
glucos
level
sucros
load
rat
main
role
activ
compound
function
group
like
nitro
fluro
methoxi
benzenoid
ring
may
govern
acid
behavior
mesomer
effect
respect
heterocycl
ring
probabl
assist
activ
structur
potent
compound
shown
fig
summar
data
given
tabl
respect
alam
et
al
synthes
carboxamid
antihypertens
agent
synthes
thirti
molecul
molecul
screen
antihypertens
activ
use
tailcuff
method
measur
systol
blood
pressur
activ
synthes
compound
compar
standard
drug
nifedipin
thirti
compound
five
compound
found
potent
molecul
structur
activ
relationship
sar
studi
reveal
differ
substitut
phenyl
ring
attach
pyrimidin
moieti
play
import
role
govern
antihypertens
activ
electron
releas
group
like
och
substitut
posit
increas
antihypertens
activ
substitut
phenyl
ring
also
import
substitut
benzyl
deriv
activ
seri
para
chlorosubstitut
deriv
found
activ
halogen
phenyl
ring
attach
amid
linkag
seem
signific
effect
tabl
antibacteri
activ
data
mic
mgml
valu
neg
control
aceton
activ
valu
indic
lgml
antihypertens
activ
structur
potent
molecul
shown
fig
summar
data
given
tabl
sondhi
et
al
synthes
mono
biand
tricycl
pyrimidin
deriv
evalu
analges
activ
synthes
ten
molecul
screen
use
phenyl
quinon
writh
assay
ibuprofen
taken
standard
drug
comparison
test
compound
analges
activ
synthes
compound
exhibit
activ
mgkg
dose
respect
structur
potent
compound
shown
fig
motil
express
highli
motil
low
sluggish
irrevers
dead
ni
inhibit
khanag
et
al
synthes
evalu
new
pyrimidin
deriv
contain
synthes
compound
screen
anticonvuls
activ
maxim
electroshock
seizur
method
me
albino
mice
use
studi
anim
stimul
corneal
electrod
current
puls
hz
appli
test
drug
given
intraperiton
destruct
hind
limb
tonic
extens
spasm
record
anticonvuls
activ
test
compound
suspend
methyl
tabl
effect
compound
standard
antidiabet
drug
metformin
oral
sucros
toler
ostt
post
sucros
load
normal
rat
cellulosewat
mixtur
preparatori
screen
compound
administ
intraperiton
inject
three
dose
level
mgkg
anticonvuls
activ
assess
h
h
interv
administr
anticonvuls
efficaci
evalu
maxim
electroshockinduc
seizur
me
screen
data
compound
present
tabl
structur
given
fig
screen
compound
compar
standard
drug
phenytoin
carbamazepin
compound
found
potent
molecul
among
seri
electron
withdraw
group
substitut
phenyl
ring
sixth
posit
dihydropyrimidin
show
mark
increas
anticonvuls
activ
kumar
et
al
synthes
thirti
two
compound
synthes
molecul
screen
antioxid
dpph
free
radic
form
assay
reduc
correspond
hydrazin
react
hydrogen
donor
dpph
radic
purpl
colour
upon
reaction
hydrogen
donor
antioxid
chang
yellow
colour
discolour
assay
evalu
addit
antioxid
test
compound
dpph
solut
ethanol
decreas
absorb
measur
fig
ic
valu
attri
et
al
cowork
synthes
deriv
evalu
antioxid
antibacteri
activ
antioxid
activ
determin
use
dpph
free
radic
scaveng
cupric
reduc
antioxid
capac
cuprac
assay
dpph
assay
basic
use
determin
free
radic
scaveng
properti
antioxid
compound
gallic
acid
quercitin
use
standard
compound
work
solut
test
extract
standard
prepar
methanol
dark
color
dpph
radic
solut
presenc
antioxid
compound
chang
yellow
color
diphenylpicrylhydrazin
absorb
solut
gener
decreas
differ
concentr
test
solut
prepar
mgml
mg
ml
mgml
mgml
pipet
test
tube
volum
adjust
ml
use
methanol
ml
dphh
solut
mm
mix
ml
sampl
standard
separ
sampl
vortex
incub
dark
min
chang
absorb
measur
nm
use
spectrophotomet
absorb
measur
radic
scaveng
activ
express
percent
inhibit
dpph
racdic
calcul
use
follow
equat
inhibit
control
absorb
sampleabsorb
notic
declin
concentr
dpph
radic
term
inhibit
reveal
due
scaveng
abil
test
compound
percent
inhibit
test
compound
rang
ppm
standard
gallic
acid
quercitin
exhibit
inhibit
percentag
respect
wherea
compound
found
show
highest
percent
inhibit
comparison
remain
test
compound
wherea
ppm
gallic
acid
quercitin
possess
inhibit
percent
respect
test
compound
show
decreas
percent
inhibit
compound
found
poss
lowest
inhibit
percentag
thu
final
compound
reveal
moder
antioxid
activ
comparison
standard
compound
compound
found
promis
antioxid
describ
fig
cuprac
assay
wide
use
determin
total
antioxid
capac
antioxid
compound
basic
prinicipl
employ
assay
redox
reduct
cu
ii
cu
monitor
chang
absorb
nm
redox
reaction
result
cuprac
reagent
cu
ii
neocuproin
cu
nc
antioxid
aoh
form
cuprac
chromophor
cu
neocuproin
cu
nc
chelat
cuprac
reagent
solut
prepar
mix
ml
copper
ii
chlorid
ml
neocuprin
solut
ml
ammonium
acet
buffer
ph
sampl
solut
distil
water
ad
mix
obtain
total
volum
ml
reduct
capabl
assess
increas
absorb
reaction
mixtur
result
obtain
cuprac
assay
easili
extend
possibl
vivo
reaction
antioxid
assay
basic
perform
physiolog
ph
closer
absorb
cu
chelat
form
result
redox
reaction
reduc
antioxid
measur
nm
color
possibl
due
format
cu
nc
chelat
increas
absorpt
indic
higher
antioxid
activ
compound
show
moder
activ
comparison
standard
compound
compound
found
reduc
copper
ion
cu
ii
cu
concentrationdepend
manner
ppm
compound
found
highest
absorb
valu
comparison
standard
gallic
acid
quercitin
absorb
valu
respect
describ
fig
wherea
lowest
concentr
ppm
absorb
test
compound
rang
compound
possess
lowest
absorb
valu
thu
conclus
state
lower
concentr
compound
show
antioxid
activ
pyrimidin
deriv
exhibit
anticanc
activ
via
interact
differ
enzym
like
tyrosinas
cytochrom
glutathion
assist
receptor
like
somaostatin
estrogen
progesteron
receptor
agbaj
et
al
synthes
hexahydropyrimidin
deriv
synthes
seri
seventeen
molecul
synthes
compound
screen
cytotox
colo
cell
line
among
seri
seventeen
molecul
four
compound
found
potent
analog
compound
show
highest
activ
ic
valu
mm
respect
compound
found
potent
molecul
ic
mm
anticanc
studi
show
compound
repres
novel
lead
develop
structur
potent
molecul
shown
fig
ic
valu
differ
substitut
basic
ring
differenti
differ
colour
yadlap
et
al
synthes
diarylpyrazol
ligat
dihydropyrimidin
synthes
compound
screen
vitro
anticanc
activ
human
breast
cancer
cell
line
synthes
twenti
three
compound
six
compound
found
activ
compound
screen
use
srb
assay
protocol
compound
test
four
dose
level
experi
repeat
thrice
six
compound
found
inhibit
growth
cell
line
gi
concentr
compound
caus
inhibit
cell
growth
exhibit
excel
growth
inhibit
cell
line
compound
found
potent
molecul
among
six
compound
compound
show
affin
inhibit
cell
growth
gi
mm
compound
also
show
good
dose
respons
structur
activ
relationship
sar
studi
suggest
compound
contain
thiogroup
potent
compound
contain
oxogroup
sar
studi
show
presenc
thiourea
function
group
dhpm
enhanc
anticanc
activ
type
scaffold
structur
potent
compound
given
fig
ic
valu
holla
et
al
synthes
thiazolodihydropyrimidinon
anticanc
agent
screen
synthes
compound
fig
sar
studi
suggest
presenc
moieti
group
substitu
tend
increas
anticanc
activ
human
relationship
antitumor
activ
lipophil
unsatur
number
carbon
atom
function
group
also
determin
set
compound
deriv
palmit
acid
set
stearic
set
b
oleic
acid
set
c
synthes
dhpm
nucleu
oxomonastrol
monastrol
analog
well
compound
lack
aromat
ring
substitut
screen
cell
viabil
rat
glioma
cell
line
screen
conduct
h
treatment
test
compound
concentr
rang
mm
compound
compound
reduc
cell
viabil
concentr
depend
manner
compound
abl
reduc
cell
viabil
mm
except
compound
howev
compound
also
screen
human
glioma
cell
line
human
describ
fig
hybrid
dhpmfatti
acid
abl
reduc
cell
viabil
mm
hybrid
oxomonastrolpalmit
acid
potent
mm
compound
found
decreas
cell
viabil
concentr
depend
manner
result
describ
hydroxyl
group
present
aromat
ring
essenti
antitumor
activ
hybrid
dhpmfatti
acid
glioma
also
observ
novel
oxomonastrol
monastrol
fatti
acid
analog
found
potent
monastrol
fatti
acid
analog
tend
impart
lipophil
charact
abl
cross
blood
brain
barrier
may
consid
promis
approach
overcom
resist
chemotherapi
help
develop
new
antitumor
drug
cytotox
activ
compound
evalu
use
organotyp
hippocamp
slice
cultur
model
cultur
compos
differ
neural
cell
prepar
day
old
male
wistar
rat
use
mcwallin
tissu
chopper
separ
icecold
hbss
ph
maintain
slice
place
millicel
cultur
insertsand
transfer
cultur
plate
medium
usual
consist
mem
hbss
hors
serum
chang
everi
three
day
experi
conduct
everi
day
cell
treat
mm
concentr
h
cellular
death
organotyp
hippocamp
cultur
determin
flourosc
imag
analysi
pi
uptak
mm
pi
ad
cultur
h
treatment
gijsen
et
al
synthes
tricycl
deriv
potent
antagonist
believ
function
mechan
chemic
stress
sensor
specif
function
protein
may
involv
role
signal
transduct
growth
control
synthes
compound
test
human
rat
channel
gener
similar
activ
monitor
human
rat
channel
compound
slightli
higher
potenc
rat
observ
concentr
test
compound
behav
true
antagonist
competit
appli
agonist
unlik
mani
electrophil
ligand
display
function
antagon
via
desensit
channel
depend
concentr
introduct
variou
substitu
aryl
substitu
strong
effect
potenc
tricycl
dhpm
orthoand
parasubstitut
compound
led
drop
activ
compar
unsubsitut
compound
varianc
metasubstitut
increas
potenc
rel
compound
especi
metamethoxi
substitut
compound
display
enhanc
potenc
addit
analog
around
compound
investig
combin
metamethoxi
substitu
addit
methoxi
substitu
led
loss
activ
increas
length
methoxi
group
prove
better
toler
compound
potent
compound
identifi
structur
ic
valu
compound
given
fig
tabl
respect
inhibit
proteas
activ
mm
select
next
assay
run
mm
ic
calcul
two
compound
found
activ
sarscov
pro
among
fourteen
molecul
ic
valu
activ
compound
given
mm
respect
compound
found
potent
molecul
sar
studi
show
r
posit
atom
substitut
nitro
group
also
r
replac
cl
group
potenc
molecul
increas
markedli
r
posit
replac
nitro
group
activ
compound
decreas
markedli
structur
molecul
shown
fig
ic
valu
see
fig
melaninconcentr
hormon
cyclic
acid
neuropeptid
found
mainli
fish
mammalian
brain
biolog
function
mch
mediat
two
receptor
mch
mch
play
vital
role
regul
food
intak
water
balanc
energi
metabol
attent
memori
psychiatr
disord
mostli
control
food
intak
stress
rodent
mice
gener
lack
mch
gene
encod
found
lean
hypophag
elev
metabol
rate
overexpress
mch
gene
mice
suspect
obes
insulin
resist
vitro
vivo
pharmacolog
mch
receptor
publish
make
attract
target
develop
antagonist
variou
mch
receptor
antagonist
develop
found
high
affin
select
toward
mch
receptor
fig
data
affin
mammalian
cell
line
express
mchr
found
k
b
nm
time
select
observ
mch
k
nm
vivo
assay
perform
rat
anorect
acid
observ
decreas
palat
food
intak
rat
without
work
malais
agent
moreov
dietinduc
obes
studi
dio
done
rat
reveal
exhibit
contin
weight
reduct
rat
also
lead
less
weight
vehicletr
counterpart
week
period
almost
time
data
obtain
standard
clinic
drug
fenfluramin
furthermor
interestingli
also
found
moder
antidepress
antianxieti
activ
differ
paradigm
howev
differ
statement
result
made
differ
research
antidepress
anxiolyt
activ
recent
millan
et
al
publish
antagonist
tend
increas
social
recognit
paradigm
rat
also
enhanc
level
acetylcholin
frontal
cortex
rat
carri
dialysi
studi
reason
dose
rhoassoci
kinas
isoform
protein
serin
threonin
kinas
enzym
associ
divers
cellular
signal
function
smooth
muscl
contract
cytoskeleton
rearrang
cell
migrat
cell
prolifer
rock
consid
potenti
therapeut
target
treatment
cardiovascular
diseas
hypertens
sehon
et
al
report
new
class
dihyropyrimidinon
deriev
amid
evalu
activ
rock
group
present
compound
found
better
oral
bioavailabl
compar
compound
therefor
studi
compound
substitut
group
found
optim
activ
found
possess
good
oral
bioavail
time
select
select
kinas
reveal
remark
ic
valu
nm
rat
aortic
contract
assay
perform
howev
ic
valu
respect
possess
signific
inhibit
appear
gener
seri
insurmount
issu
focu
shift
compound
substitut
pyridyl
ring
enzym
activ
maintain
substanti
diminish
oral
bioavail
decreas
compound
found
improv
oral
bioavail
respect
shown
fig
compound
consist
chloro
group
show
improv
halflif
rat
h
good
select
upto
fold
panel
kinas
ic
nm
improv
profil
therefor
select
vivo
efficaci
studi
use
spontan
hypertens
rat
shr
model
hypertens
reveal
drop
blood
pressur
mm
hg
singl
dose
mgkg
benign
prostat
hyperplasia
bph
progress
enlarg
prostat
gland
estim
may
affect
atleast
male
popul
unit
state
year
age
howev
incid
rate
may
increas
age
bph
result
two
mechanist
compon
mechan
dynam
compon
mechan
compon
result
increas
prostat
mass
mainli
attribut
due
enzym
respons
convers
testosteron
variou
inhibitor
enzym
finasterid
clinic
proven
reduc
size
prostat
gland
decreas
symptom
bph
dynam
compon
bph
attribut
endogen
adrenerg
tone
restrict
flow
urethra
adrenerg
receptor
antagonist
terazosin
reliev
symptom
bph
relax
lower
urinari
tract
tissu
final
reduc
prostat
urether
tone
tamsulosin
consid
prostat
select
antagonist
current
market
due
better
therapeut
index
compar
terazosin
shown
fig
recent
found
niguldipin
calcium
channel
blocker
found
potent
receptor
subtyp
antagonist
time
greater
select
receptor
subtyp
see
fig
sever
modif
done
niguldipin
skeleton
therebi
led
format
dihydropyrimidinon
moieti
two
logic
site
attach
piperidin
contain
side
chain
import
attach
posit
dhp
found
exact
structur
central
moieti
import
mode
attach
piperidin
contain
sidechain
via
amid
bond
format
dhp
carboxyl
crucial
produc
potent
select
compound
thu
heterocycl
deriv
attach
via
amid
synthes
investig
vitro
vivo
bind
affin
receptor
antagonist
bind
affin
express
k
nm
found
among
deriv
nm
found
potent
nm
greater
select
howev
combin
two
slightli
increas
potenc
similar
level
observ
nm
possess
extra
ordinari
bind
affin
receptor
subtyp
substitu
found
highli
select
time
less
potent
other
except
combin
dhp
nm
piperidin
also
examin
receptor
bind
affin
reveal
hydroxi
substitu
lead
slight
decreas
bind
affin
modest
increas
select
rel
unsubstitut
part
vs
howev
cyano
substitut
possess
addit
select
receptor
subtyp
along
bind
affin
nm
nm
triflouromethyl
group
dhp
essenti
bind
hydrogen
methyl
methoxymethyl
describ
excel
potenc
time
greater
select
rel
subtyp
polar
substitu
attach
may
limit
absorpt
therefor
alkyl
acyl
dhp
nitrogen
examin
effect
bind
affin
methyl
improv
select
methyl
decreas
possess
similar
potenc
nm
nm
vs
nm
combin
methyl
dhp
extraordinari
select
compound
obtain
howev
acyl
acetyl
nm
carbomethoxi
nm
decreas
select
potenc
observ
compound
compound
exhibit
time
greater
select
receptor
bind
affin
nm
compound
synthes
see
fig
mani
compound
also
investig
vivo
pharmacodynam
pharmacokinet
paramet
compound
test
rat
model
prostat
anesthet
rat
expos
compound
test
inhibiton
ad
mgkg
valu
contractil
respons
induc
select
agoinst
compound
contain
flouro
cyano
substitu
found
quiet
potent
ad
valu
mgkg
wherea
piperidin
x
substitu
follow
trend
oh
h
cn
vs
vs
pharmacodynam
paramet
ie
durat
action
major
compound
measur
agonist
concentr
time
greater
ad
found
short
unexplain
compound
mark
plasmahalf
live
also
found
short
durat
action
other
methyl
nitrogen
dhp
found
increas
durat
action
vitro
metabol
compound
examin
use
human
liver
microsom
prepar
mm
substrat
microsom
protein
mgml
h
lcm
ms
detect
experi
reveal
rapid
ndealkyl
piperidin
methyl
dhp
well
desatur
dhp
nucleu
pyrimidin
nucleu
primari
metabol
pathway
see
fig
compound
abl
pass
firstpass
metabol
rat
therefor
pharmacodynam
pharmacokinet
paramet
evalu
dog
compound
found
long
halflif
dog
h
thu
daili
dose
appropri
human
pharmacodynam
efficaci
select
done
canin
intraurethr
pressur
iup
assay
compound
lead
simultan
monitor
heart
rate
blood
pressur
determin
inhibit
phenylepherineinduc
chang
iup
compound
found
potent
terazosin
also
found
longer
durat
action
h
dihydropyrimidinon
prototyp
act
via
variou
mechan
emerg
potent
sever
diseas
dihydropyrimidinon
revolution
chemistri
purin
well
pyrimidin
differ
biolog
activ
make
advantag
scaffold
antagonist
natur
toward
natur
pyrimidin
make
power
candid
synthesi
variou
effect
success
molecul
number
drug
like
idoxuridin
methythiouracil
emivirin
aminophyllin
contain
dihydropyrimidinon
alreadi
discov
effect
use
prevent
treatment
multipl
diseas
dphm
deriv
versatil
molecul
explor
variou
diseas
antimicrobi
antihypertens
antihiv
anticanc
etc
research
explor
sar
well
bind
mode
molecular
model
studi
addit
recognit
ration
pictur
toward
appropri
substitut
account
effect
toxic
may
futur
skeleton
toxic
problem
relat
dihydropyrimidinon
recogn
overcom
conflict
interest
